ESOPHAGEAL CANCER DRUGS MARKET ANALYSIS

Esophageal Cancer Drugs Market, By Therapy Type (Chemotherapy (Docetaxel, Irinotecan, Trifluridine and Tipiracil, Carboplatin and Paclitaxel, Cisplatin and 5-fluorouracil, and Cisplatin with Capecitabine), Targeted Drug Therapy (Trastuzumab and Ramucirumab), and Immunotherapy (Pembrolizumab)), By Disease Indication (Adenocarcinomas, Gastrointestinal Stromal Tumors, Carcinoid Tumors, Squamous Cell Carcinoma, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis 2019 - 2027

Published In : Sep 2019
Code : CMI3036
Pages :166
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Esophageal Cancer Drugs Market - Restraints

However, high cost of therapy for the treatment of esophageal cancer is expected to restraint the market growth. For instance, as per the report published in Healthday, in 2013, cancer patients paid US$ 207,000 per year for the treatment and medications while in 1995, the cost was US$ 54,100 per year.

Moreover, the side effects caused by esophageal cancer drugs are loss of appetite and weight loss, fatigue, diarrhea, hair loss, sore mouth, hand-foot syndrome, low blood cell counts, blood clots (deep vein thrombosis), nervous system damage, and heart damage. According to the 2017 report of the American Cancer Society (ACS), side effects of esophageal cancer drugs such as Cisplatin, oxaliplatin, docetaxel, and paclitaxel can cause major damage to nerves outside the brain and spinal cord.